Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

 Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1

If Approved, Tarlatamab Would be the First BiTE® Therapy for a Major Solid Tumor

FDA Target Action Date is June 12, 2024

https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-amgens-tarlatamab-application-for-advanced-small-cell-lung-cancer-302014639.html